AZNCF:OTC-AstraZeneca PLC (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 152.66

Change

-0.14 (-0.09)%

Market Cap

USD 241.92B

Volume

700.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
RHHBY Roche Holding Ltd ADR

N/A

USD 258.74B
RHHVF Roche Holding AG Participation

-6.28 (-2.05%)

USD 258.74B
RHHBF Roche Holding AG

N/A

USD 258.74B
SNYNF Sanofi

N/A

USD 142.76B
CHGCY Chugai Pharmaceutical Co Ltd A..

-0.12 (-0.51%)

USD 83.22B
DSNKY Daiichi Sankyo Co Ltd ADR

N/A

USD 63.77B
ALPMF Astellas Pharma Inc

N/A

USD 21.46B
ALPMY Astellas Pharma Inc

N/A

USD 21.25B
RICFY Recordati Industria Chimica e ..

N/A

USD 11.87B
KYKOF Kyowa Kirin Co. Ltd

N/A

USD 11.02B

ETFs Containing AZNCF

C068:F 9.54 % 0.00 %

N/A

N/A
C068:XETRA 9.54 % 0.00 %

N/A

N/A
INAG 1.34 % 0.00 %

N/A

N/A
DBAW Xtrackers MSCI All World .. 0.00 % 0.41 %

+0.41 (+0%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.54% 67% D+ 66% D+
Dividend Return 2.20% 58% F 35% F
Total Return 15.74% 71% C- 66% D+
Trailing 12 Months  
Capital Gain 14.37% 64% D 63% D
Dividend Return 2.22% 42% F 32% F
Total Return 16.58% 68% D+ 63% D
Trailing 5 Years  
Capital Gain 79.07% 94% A 83% B
Dividend Return 14.70% 61% D- 48% F
Total Return 93.78% 91% A- 83% B
Average Annual (5 Year Horizon)  
Capital Gain 9.58% N/A N/A 54% F
Dividend Return 11.86% N/A N/A 53% F
Total Return 2.28% N/A N/A 46% F
Risk Return Profile  
Volatility (Standard Deviation) 10.09% N/A N/A 96% N/A
Risk Adjusted Return 117.52% N/A N/A 99% N/A
Market Capitalization 241.92B 85% B 100% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.